Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions develops and supplies cell processing tools and bioproduction products for the cell and gene therapy market and broader biopharma customers. Company news commonly covers financial results from continuing operations, demand for biopreservation media, and the role of its products in maintaining biologic material during collection, development, manufacturing, storage, distribution, and thawing.
Recurring updates also include product-portfolio expansion, supply agreements for cell and gene therapy manufacturing inputs, CellSeal vial systems, human platelet lysate products, cytokine and growth factor distribution, and research activity tied to biopreservation and cryopreservation technologies.
BioLife Solutions (NASDAQ: BLFS) announced it will release its third quarter 2021 financial results after market close on November 11, 2021. Following the release, a conference call is scheduled for 4:30 PM ET where management will discuss the financial results and provide a business update. Investors can access the call through the company’s Investor Relations page or via phone. BioLife is a leading supplier of bioproduction tools and services for the cell and gene therapy market.
Biolife Solutions (NASDAQ: BLFS) has announced the opening of a new 40,000 square-foot biorepository Center of Excellence in Amsterdam, enhancing its support for cell and gene therapies. The facility features a CAR-T cell storage suite and more than 300 ultra-low temperature freezers, aimed at improving global access to biologic therapies. Already partially contracted to a major pharmaceutical client, the facility is part of BioLife's commitment to innovative infrastructure and biostorage best practices, ensuring the integrity of sensitive biological materials.
BioLife Solutions (NASDAQ: BLFS) announced a collaboration with a top 10 global pharmaceutical company to employ its CryoStor freeze media, evo cold chain management platform, and SciSafe storage services for the launch of a new CAR T-cell therapy. This engagement represents BioLife's strategic push in the cell and gene therapy market. CEO Mike Rice highlighted the company's commitment to supporting bioproduction needs. Currently, CryoStor is used in the manufacturing of several approved therapies and is embedded in additional therapies expected to gain regulatory approval soon.
BioLife Solutions (Nasdaq: BLFS) announced the appointment of Joydeep Goswami to its board of directors, effective October 1, 2021. Goswami, who previously held senior roles at Illumina and Thermo Fisher Scientific, will replace retiring board member Andrew Hinson. The addition aims to bolster the company's strategic planning and partnerships, enhancing shareholder value. CEO Mike Rice expressed excitement about Goswami's expertise in life sciences, anticipating a positive impact on business growth.
BioLife Solutions (Nasdaq: BLFS) announced the retirement of CFO Roderick de Greef, effective December 31, 2021. He will assist in the transition until March 31, 2022. De Greef has been vital to the company for over 20 years, significantly impacting its growth and funding strategies. The company has engaged executive search firm Strawn Arnold to find his successor. CEO Mike Rice expressed gratitude for de Greef's contributions, emphasizing his instrumental role during a period of significant expansion.
BioLife Solutions (Nasdaq: BLFS) has filed a Form S-3 registration statement with the SEC to register approximately 10.7 million shares of restricted common stock. These shares are held by stockholders from acquired companies including Global Cooling, Inc. and Sexton Biotechnologies, and also include shares from Casdin Capital. CEO Mike Rice emphasized the strategic importance of recent acquisitions in a growing market. The filing is in compliance with obligations related to these acquisitions, and no new shares are being issued.
BioLife Solutions (Nasdaq: BLFS) announced the closing of its acquisition of Sexton Biotechnologies on September 1, 2021. This acquisition enhances BioLife’s portfolio with proprietary bioproduction tools, such as closed vials for cell therapy packaging and human platelet lysate media, integral to over 50 ongoing clinical trials. CEO Mike Rice emphasized the strategic significance of this acquisition for expanding revenue and capabilities in the cell and gene therapy market, marking it as BioLife's sixth acquisition in just over two years.
BioLife Solutions (BLFS) announced its inclusion in the S&P SmallCap 600 Index, effective August 30, 2021. This recognition reflects the company’s commitment to enhancing shareholder value through its innovative bioproduction products for cell and gene therapies. The S&P SmallCap 600 Index comprises small-cap companies that meet specific liquidity and financial viability criteria. BioLife's CEO, Mike Rice, emphasized this milestone as a tribute to the team's dedication to customer satisfaction and long-term growth.
BioLife Solutions (BLFS) reported a record second quarter 2021 revenue of $31.2 million, reflecting a 215% year-over-year increase. The growth was fueled by acquisitions, including Stirling Ultracold, contributing $13.3 million. Adjusted net income was $422,000 for the six months ending June 30, while earnings per diluted share rose to $0.19. The company also updated its 2021 revenue guidance to between $108 million and $117 million, showing continued confidence in their market position.
On August 9, 2021, BioLife Solutions (NASDAQ: BLFS) announced its agreement to acquire Sexton Biotechnologies for a total deal value of $30 million. This acquisition aims to enhance BioLife's capabilities in the cell and gene therapy sector by integrating Sexton's innovative technologies such as CellSeal cryogenic storage vials and the Signata CT-5 fluid handling system. The merger is expected to strengthen BioLife's product offerings and relationships with cell and gene therapy developers, positioning the combined organization for further growth.